The cost-effectiveness of augmenting immunization against hepatitis B infection with hepatitis B immunoglobulin (HBIG) remains controversial, particularly for the subpopulation of babies of HBsAg+/HBeAg2 mothers that are considered as low-infective. We aimed to evaluate the effectiveness of vaccine alone compared with vaccine plus HBIG for the immunization of babies of HBsAg+/HBeAg2 mothers.
Introduction
Hepatitis B (HB) is a chronic viral infection, associated with considerable morbidity and mortality, and social and economical implications. Recent reports suggest that 2 billion people have been infected with HB virus (HBV) worldwide. Additionally, more than 240 million people have been reported to present with long-term liver infections. 1 Mother-to-child transmission, occurring during the perinatal period, is the most important cause of chronic infection, accounting for 35% -50% of carriers. 2 Evidence suggests that the mother's serological status (HBsAg/HBeAg) may have a role in perinatal transmission. 3 Specifically, data deriving from relevant studies suggest that the risk of infection in infants born to HBsAg+/HBeAg+ mothers is considerably higher compared with those born to HBsAg+/HBeAg2 mothers. 4 -6 On the other hand, cases of fulminant hepatitis have also been reported for infants born to HBeAg2 mothers. 7 -9 The combined use of vaccine and HB immunoglobulin (HBIG) within 24 h of birth is reported to reduce the risk of chronic HB infection to 10% -15% and , 1% for infants born to HBeAg+ and HBeAg2 mothers, respectively. 7 Yet, due to the considerable cost of screening for HBeAg positivity and administration of HBIG, some countries with inadequate resources use only hepatitis vaccine for immunization of infants born to HBsAg+ mothers, while most do not screen for the maternal HBeAg status. 7, 10 The literature provides controversial evidence regarding the effectiveness of administration of HBIG in infants born to HBeAg+/HBeAg2 mothers. 3, 11, 12 The aim of our study was to evaluate the effectiveness of vaccine alone compared with combined immunization (HBIG and vaccine) of infants born to HBsAg+/HBeAg2 mothers by performing a meta-analysis of relevant studies.
Methods

Data sources
The articles included in this meta-analysis were retrieved from searches performed in PubMed and Scopus databases. Both of these databases were last assessed in June 2014. An additional search in the Cochrane Central Register of Controlled Trials was performed. Bibliographies were also hand-searched. The registry of clinical trials, namely 'ClinicalTrials. gov', was also searched.
Study selection criteria
A study was regarded as eligible for inclusion in this meta-analysis if it provided comparative data regarding the effectiveness of HB immunization strategies, including vaccine only, compared with the combination of vaccine plus HBIG in babies of HBsAg+/HBeAg2 mothers. Studies providing relevant data concerning anti-HBeAg+ mothers were regarded as eligible for inclusion. Articles published in languages other than English, German, Italian or Spanish were regarded as not eligible for inclusion. Specifically, our search revealed two potentially relevant studies that were published in Chinese but were not included because of the language barrier. 13, 14 Case reports and abstracts presented in scientific conferences were also excluded.
Data extraction, definitions and outcomes
Data extracted consisted of specific study/population characteristics (Table 1 ) and the respective evaluated outcomes (Table S1 , available as Supplementary data at JAC Online). Occurrence of infection (the primary outcome of our meta-analysis) was defined as HBsAg positivity of the evaluated babies at any follow-up visit .1 month following immunization. Vaccine efficacy was evaluated as a cumulative outcome that comprised the different definitions provided by the individual evaluated studies. Seroprotection rate was defined as the proportion of the evaluated neonates with anti-HBsAg ≥10 IU/L at the time of the follow-up assessment. Transition to carrier state was also evaluated as an additional effectiveness outcome.
Data analysis
A meta-analysis was performed regarding the evaluated outcomes; randomized controlled trials (RCTs) and non-randomized studies were grouped and presented separately. We also performed a sensitivity analysis including studies that provided separate data for the subgroup of the included neonates born to HBsAg+/HBeAg2 mothers. The Jadad score was used for methodological quality assessment of the included RCTs (a score .2 points denoted adequate methodological quality), 15, 16 whereas the Newcastle -Ottawa Scale was used for non-randomized comparative studies.
Statistical analysis
A random effects model was used for the estimation of the pooled ORs and the respective 95% CIs for the analysed outcomes. 17 The I 2 test was used to test for statistical heterogeneity among the analysed studies. 18 Funnel plots testing for publication bias were also performed. All statistical analyses were performed with the Review Manager (RevMan) version 5.0 Software (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, 2008).
Results
Nine studies were regarded as eligible for inclusion in our review/ meta-analysis. 12,19 -26 The detailed process of the literature search is depicted in Figure 1 .
Characteristics of the included studies
Four of the nine included studies were RCTs. 19, 22, 23, 26 Three were published after 2011. 19 -21 One study evaluated children aged 6 months to 10 years, 21 whereas all other included studies evaluated neonates/infants. In one of the two most recent included studies, HBIG was administered to all evaluated infants, who also received three doses of HB vaccine. 20 Yet in this study, HBIG was administered within 24 h of birth by protocol to all newborns born to HBeAg+ mothers, whereas for infants born to HBeAg2 mothers, the administration of HBIG was optional and self-paid. 20 
Characteristics of the included patients
Seven studies provided data exclusively for neonates born to HBsAg+/HBeAg2 mothers, 12,20 -25 whereas the remaining two provided cumulative data for neonates born to HBsAg+ mothers, regardless of their HBeAg status. 19, 26 In these two specific studies HBeAg2 mothers constituted the majority (.72%) of the included HBsAg+ mothers.
Outcomes
Data referring to infection and seroprotection rate were incorporated into the meta-analysis. The limited availability and considerable heterogeneity of data regarding the remaining evaluated outcomes precluded us from performing a meta-analysis regarding the remaining outcomes.
Analysed outcomes
Occurrence of infection
Four studies provided relevant data 12, 21, 25, 26 (one RCT 26 ) . No difference was found regarding the occurrence of infection between babies immunized with vaccine alone, compared with those immunized with vaccine and HBIG (four studies, 3426 patients, OR ¼ 0.82, 95% CI ¼ 0.41 -1.64; Figure 2 ). Additionally, in one of the two recent studies that were not included in statistical analysis, no cases of HBV infection were identified in any of the two compared groups, 20 whereas in the other study, occult infection was found to be more common in the (vaccine+HBIG) group for all included neonates. 19 
Seroprotection rate
Four studies provided relevant data 12, 23, 25, 26 (two RCTs 23, 26 
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the compared groups (four studies, 1323 patients, OR¼ 1.24, 95% CI ¼ 0.97-1.58, Figure 3 ).
Sensitivity analysis
No difference was found regarding the occurrence of infection between the compared groups [three studies (0 RCTs), 2041 patients, OR ¼ 1.16, 95% CI ¼ 0.26 -5.17; Figure 4 ]. 12, 21, 25 Similarly, no difference was found regarding the seroprotection rate between the compared groups [three studies (one RCT 19 ), 258 patients, OR ¼ 2.2.1, 95% CI ¼ 0.57 -8.41, Figure 5 ]. 12, 23, 24 Funnel plots were generated in order to assess publication bias ( Figure S1 ).
Other evaluated outcomes
Four studies provided data regarding the transition to carrier state 12,22 -24 (two RCTs 22, 23 ). In three of these four studies, none of the babies became an HBV carrier in either of the compared groups. 12, 23, 24 The detailed data presented from the fourth study are presented in Table S1 . 22 Two of the included studies presented data with regard to vaccine efficacy 21, 26 (detailed data are presented in Table S1 ). None of the included studies reported safety data regarding the use of the compared immunization strategies.
Additional outcomes were reported from one of the three most recent included studies. 21 Specifically, fulminant hepatic failure was reported in 1/1050 (0.09%) of the neonates who were immunized with HB vaccine only, compared with none of the neonates 0/723 (0%) who were immunized with the combination of HB vaccine and HBIG. 21 Moreover, the cost -benefit analysis for preventing fulminant hepatic failure, which was performed in this study, favoured the co-administration of HB vaccine and HBIG (Table S1 ). 21 
Discussion
The main finding of our study is that no difference was observed in occurrence of HB infection in neonates of HBsAg+/HBeAg2 mothers who received either combined immunization (vaccine plus HBIG) or vaccine alone. This finding was consistent with regard to seroprotection rate. Limited data were available regarding the other evaluated outcomes, which precluded us from incorporating the above-mentioned outcomes in a meta-analysis.
To our knowledge, this is the first meta-analysis to date that has focused on the evaluation of the effectiveness and safety of the above-mentioned immunization strategies in neonates of HBsAg+/HBeAg2 mothers. Indeed, in a previous relevant meta-analysis only 3 of 29 included studies involved HBsAg+/ 
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HBeAg2 mothers. 3 In that meta-analysis, the combination of vaccine plus HBIG reduced the occurrence of HB in neonates, compared with HBV vaccine alone, regardless of the mother's serological status. 3 On the other hand, according to the findings of a recent relevant study that was not included in our statistical analysis, occult infection was more common in neonates who Total events 5 Heterogeneity: t 2 = 0.00; c 2 = 0.44, df = 2 (P = 0.80); I 2 = 0% Test for overall effect: Z = 0.20 (P = 0.84) Heterogeneity: Not applicable Test for overall effect: Z = 0.73 (P = 0.47) Total events Heterogeneity: t 2 = 0.00; c 2 = 0.70, df = 3 (P = 0.87); I 2 = 0% Test for overall effect: Z = 0.56 (P = 0.58) Systematic review 401 JAC received both vaccine and HBIG, possibly due to the immune pressure induced by HBIG. 19 Most recently, a meta-analysis that aimed to evaluate the response to recombinant vaccine among infants irrespective of the maternal HBsAg status reported that seroprotection rates did not vary appreciably by HBIG administration. 27 In our meta-analysis, the combination of vaccine plus HBIG was not significantly associated with lower seroprotection rates, compared with HBV vaccine alone. The small number of studies included in the above-mentioned analysis may possibly account for this particular finding. The long-term effects of this observation may remain unknown, but the literature provides evidence that the co-administration of HBIG may offer additional protection during early infancy from horizontal transmission, in the event of delayed administration of the second vaccine dose. 12, 28 It is noteworthy that data regarding the safety of the evaluated immunization strategies were not reported in any of the studies included in our meta-analysis. Indeed, published evidence suggests that safety data regarding immunization strategies, mainly vaccines, are scarcely reported in the literature. 29, 30 Another important outcome is the risk of chronic HB infection in neonates of HBsAg+/HBeAg2 mothers. In our study, the scarcity of data regarding the occurrence of chronic infection precluded the evaluation of this outcome in a meta-analysis. On the other hand, although the risk of chronic infection in children born to HBsAg+/HBeAg2 mothers is low, there have been several reports of fulminant acute hepatitis, thus supporting the need for effective prevention of transmission. 9,31 -33 Yet the very low incidence of fulminant hepatitis (,1% of cases), in view of the high cost of HBIG, warrants further investigation. 21 In particular, a Total events 5 Heterogeneity: t 2 = 0.00; c 2 = 0.44, df = 2 (P = 0.80), I 2 = 0% Test for overall effect: Z = 0.20 (P = 0.84) Total (95% CI) Test for subgroup differences: c 2 = 0.02, df = 1 (P = 0.90), I 2 = 0% Figure 5 . Seroprotection rate in neonates born to HBsAg+/HBeAg2 mothers, who received either vaccine or the combination of vaccine and HBIG, in studies providing exclusive data for neonates born to HBsAg+/HBeAg2 mothers and not for the total study population. The vertical line denotes no difference between the compared groups. Pooled ORs and 95% CIs are depicted by diamond shapes and horizontal lines, respectively. Squares indicate individual point estimates. The size of the square denotes the weight that each individual study has in the meta-analysis. Non-randomized comparative studies and RCTs are presented separately as subgroups.
recently published cost-effectiveness study, which implemented a decision-analysis approach, suggested that administration of HBIG to neonates of HBsAg+ mothers seems to be a costeffective addition to universal vaccination, especially in clinical settings with a healthcare infrastructure that may support this strategy. 34 Recently, the role of maternal HBV viraemia has been further investigated. 35 Published evidence suggests that increased maternal HBV viral load has been associated with breakthrough infections despite the administration of appropriate prophylaxis in babies of both HBeAg+ and HBeAg2 mothers. 23 Yet HBV-DNA PCR assays are also expensive and difficult to perform. In this regard, further cost-effectiveness studies evaluating the inclusion of HBeAg status as part of prenatal screening tests may also provide useful data.
Our meta-analysis has some limitations. Firstly, the number of individual studies that were finally incorporated into the statistical analysis was rather small. An explanation that may account for this observation is that most of the relevant studies focus on HBsAg+/HBeAg+ mothers, who are considered to be more infective to their offspring compared with HBsAg+/HBeAg2 mothers. 34 However, current evidence suggests that the importance of transmission from HBeAg2 chronic HB carriers in highly endemic countries has been underestimated. 35 Another fact that may account for the scarcity of data regarding HBsAg+/HBeAg2 mothers is that most of the included studies involve populations from endemic countries where the majority of HBsAg+ mothers are also HBeAg+. Furthermore, restrictions imposed by language of publication should also be acknowledged as a limitation. Finally, only four of the nine included studies were RCTs. Despite ethical considerations, this may be explained by the fact that, in some clinical settings, the administration of HBIG is determined by parental will. 21 Specifically, in some clinical settings the augmentation of hepatitis B immunization in babies born to HBsAg+/ HBeAg2 mothers with HBIG is self-paid and remains at the discretion of parents. 21 In conclusion, the addition of HBIG to vaccination seems to be equally effective to vaccine alone for offspring of HBsAg+/ HBeAg2 mothers with regard to the prevention of infection. Further investigation, particularly cost-effectiveness studies, is warranted in order to clarify the potential benefit of additional HBIG administration to all newborns of HBsAg+ mothers regardless of their HBeAg status.
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